RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis

Sekine, 2008, Emerging ethnic differences in lung cancer therapy, Br J Cancer, 99, 1757, 10.1038/sj.bjc.6604721 Zhou, 2011, East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians, Chin J Cancer, 30, 287, 10.5732/cjc.011.10106 Hsu, 2018, Overview of current systemic management of EGFR-mutant NSCLC, Ann Oncol, 29, i3, 10.1093/annonc/mdx702 Dearden, 2013, Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap), Ann Oncol, 24, 2371, 10.1093/annonc/mdt205 Bauml, 2013, Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?, Lung Cancer, 81, 347, 10.1016/j.lungcan.2013.05.011 Soraas, 2018, Geographic variation in the measured frequency of EGFR mutations in lung adenocarcinoma may be explained by interethnic genetic variation, J Thorac Oncol, 13, 454, 10.1016/j.jtho.2017.11.128 Park, 2016, Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial, Lancet Oncol, 17, 577, 10.1016/S1470-2045(16)30033-X Sheng, 2016, Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis, Eur J Clin Pharmacol, 72, 1, 10.1007/s00228-015-1966-0 Soria, 2018, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer, N Engl J Med, 378, 113, 10.1056/NEJMoa1713137 Wu, 2017, Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial, Lancet Oncol, 18, 1454, 10.1016/S1470-2045(17)30608-3 Choi, 2013, EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital, PLoS ONE, 8, e56011, 10.1371/journal.pone.0056011 Gahr, 2013, EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice, Br J Cancer, 109, 1821, 10.1038/bjc.2013.511 Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X Kawaguchi, 2010, J Thorac Oncol, 5, 1001, 10.1097/JTO.0b013e3181e2f607 Ou, 2009, Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status, J Thorac Oncol, 4, 1083, 10.1097/JTO.0b013e3181b27b15 Gazdar, 2009, Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors, Oncogene, 28, S24, 10.1038/onc.2009.198 Ahn, 2010, Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era, J Thorac Oncol, 5, 1185, 10.1097/JTO.0b013e3181e2f624 Gibson, 2019, Impact of Asian ethnicity on outcome in metastatic EGFR-mutant non-small cell lung cancer, Asia-Pac J Clin Oncol, 15, 343, 10.1111/ajco.13234 Saito, 2019, Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial, Lancet Oncol, 20, 625, 10.1016/S1470-2045(19)30035-X Zhou, 2019, CTONG 1509: phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC, Ann Oncol, 30, 10.1093/annonc/mdz260.002 Rosell, 2017, Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial, Lancet Respir Med, 5, 435, 10.1016/S2213-2600(17)30129-7 Stinchcombe, 2019, Effect of erlotinib plus Bevacizumab vs Erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: a phase 2 Randomized Clinical Trial, JAMA Oncol, 5, 1448, 10.1001/jamaoncol.2019.1847 Le, 2021, Dual EGFR-VEGF pathway inhbition: a promising strategy for patients with EGFR-mutant NSCLC, J Thorac Oncol, 16, 205, 10.1016/j.jtho.2020.10.006 Nakagawa, 2019, Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 20, 1655, 10.1016/S1470-2045(19)30634-5 CYRAMZA USPI®. Eli Lilly. Version 06/ 2020. TARCEVA USPI®. Genentech. Version 10/ 2016. Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 Cox, 1972, Regression Models and Life Tables (with Discussion), J. R Stat. Soc., 34, 187 Sheng, 2016, Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis, Eur J Clin Pharmacol, 72, 1, 10.1007/s00228-015-1966-0 Garon, 2014, Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial, Lancet, 384, 665, 10.1016/S0140-6736(14)60845-X Ramalingam, 2020, Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC, N Engl J Med, 382, 41, 10.1056/NEJMoa1913662 2020 [ESMO] European Society for Medical Oncology. Ann Oncol (2018) 29 (suppl 4): iv192–iv237. https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer. Accessed 17 November 2020. Yu, 2013, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers, Clin Cancer Res, 19, 2240, 10.1158/1078-0432.CCR-12-2246 Mayo-de-Las-Casas, 2017, Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions, Ann Oncol, 28, 2248, 10.1093/annonc/mdx288 Seto, 2014, Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study, Lancet Oncol, 15, 1236, 10.1016/S1470-2045(14)70381-X